About 10 results found for searched term "Cot inhibitor-2" (0.178 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M14163 | Cot inhibitor-2 | MAPKAPK2/MAP3K/MAP4K |
| Cot inhibitor-2 is a potent, selective and orally active cot (Tpl2/MAP3K8) inhibitor with an IC50 of 1.6 nM. Cot inhibitor-2 inhibts TNF-α production in LPS-stimulated human whole blood with an IC50 of 0.3 μM. | ||
| M9681 | JBSNF-000088 (6-Methoxynicotinamide) | Others |
| 6-Methoxynicotinamide | ||
| Jbsnf-000088 (6-methoxynicotinamide) is a niacinamide (NA) analogue, which is a potent NNMT inhibitor. Jbsnf-000088 (6-methoxynicotinamide) is a niacinamide n-methyl transferase (NNMT) inhibitor. The IC50 of monkey NNMT and mouse NNMT were 1.8 µM, 2.8 µM and 5.0 µM, respectively. In animal models of metabolic diseases, JBSNF-000088 inhibits NNMT activity, reduces MNA levels and drives insulin sensitization and regulates glucose. | ||
| M10937 | Edicotinib | CSF-1R (c-Fms) |
| JNJ-40346527; JNJ-527 | ||
| Edicotinib (JNJ-40346527) is a potent, selective, blood-brain permeable and orally active CSF-1R inhibitor.IC50 3.2 nM. Edicotinib has less inhibitory effect on KIT and FLT3,IC50 The values are 20 nM and 190 nM, respectively. Edicotinib inhibits the expansion of microglia, weakens the proliferation of microglia and neurodegenerative degeneration. Edicotinib can be used in the study of Alzheimer's disease and rheumatoid arthritis. | ||
| M11322 | JBSNF-000088 | Others |
| 6-Methoxynicotinamide | ||
| Jbsnf-000088 (6-methoxynicotinamide) is an analogue of Nicotinamide (NA), and is an effective inhibitor of Nicotinamide n-methyltransferase (NNMT). The IC50 values for human NNMT(hNNMT), Monkey NNMT(mkNNMT) and mouse NNMT(mNNMT) were 1.8 µM, 2.8 µM and 5.0 µM. | ||
| M14162 | Cot inhibitor-1 | p38 MAPK |
| Cot inhibitor-1 (compound 28) is a selective tumor progression loci-2 (Tpl2) kinase inhibitor with an IC50 of 28 nM. Cot inhibitor-1 shows an inhibition of TNF-alpha production in human whole blood with an IC50 of 5.7 nM. | ||
| M20823 | OT-82 | NAMPT |
| OT-82 is a novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with average IC50s of 13.03 nM in non-HP cancer cells and 2.89 nM in HP cancer cells, respectively. | ||
| M20843 | NNMTi | Others |
| Compound 1k, NNMT inhibitor | ||
| NNMTi (Compound 1k, NNMT inhibitor) is a potent nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 of 1.2 μM. | ||
| M29219 | T-1095 | SGLT |
| T-1095 is a selective and orally active Na+-glucose cotransporter (SGLT) inhibitor with IC50s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research. | ||
| M30847 | Tofogliflozin | SGLT |
| CSG452 | ||
| Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2. | ||
| M52757 | Azemiopsin | AChR/AChE |
| Azemiopsin is a potent nicotinic acetylcholine receptor (nAChR) inhibitor with IC50s of 0.18 μM and 22 μM against T. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
